Tuesday, August 9, 2022 Daily Archives

Sartorius lays out $500m to buy recombinant albumin firm Albumedix

Sartorius Stedim Biotech will add a portfolio of recombinant albumin-based products used in drug manufacture and a 72,000 square-foot production facility through the acquisition of Albumedix. During its second quarter financial call last month, bioprocess vendor Sartorius spoke about its desire to acquire complementary technologies and innovation through a war chest of around €10 billion ($10.2 billion) firepower at its disposal. Less than three weeks on, and the firm has pulled the trigger, agreeing to buy Albumedix for approximately £415…

Astellas eyes AMD cell therapy trial restart after manufacturing tweaks

Astellas is set to restart trials for its age-related macular degeneration (AMD) program ASP7317 after improving production and analytical process for the embryonic stem cell-derived candidate. Astellas added ASP7317 to its pipeline through the acquisition of Ocata Therapeutics in 2015. The cell therapy, derived from pluripotent human stem cells, is being investigated as a potential treatment for people with dry AMD. But a Phase I trial enrolment was voluntarily put on hold by Astellas last year “due to the time…

Comprehensive Cell and Gene Therapy Testing Capabilities

With the promise to enhance treatment, greatly reduce side effects, and potentially cure many types of diseases and disorders, Advanced Therapy Medicinal Products (ATMP), such as gene and cell therapy products, are in high demand, and biopharma companies are in a race to the clinic. However, these technologies are very complex in nature and are vastly different than traditional biopharmaceutical products, especially when it comes to the use of these products for personalized medicine. The complexities span the development pipeline,…